De Solidarite Des Travai Fonds Sells 4,575 Shares of enGene Holdings Inc. (NASDAQ:ENGN) Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $15.01, for a total transaction of $68,670.75. Following the transaction, the insider now directly owns 3,084,107 shares in the company, valued at $46,292,446.07. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Monday, April 22nd, De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock. The stock was sold at an average price of $15.00, for a total value of $717,810.00.

enGene Trading Up 3.1 %

Shares of enGene stock opened at $15.26 on Wednesday. enGene Holdings Inc. has a 52-week low of $6.69 and a 52-week high of $43.00. The firm has a 50-day moving average price of $16.27.

Institutional Investors Weigh In On enGene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENGN. Fcpm Iii Services B.V. bought a new stake in enGene in the 4th quarter valued at about $80,097,000. BVF Inc. IL bought a new stake in shares of enGene during the fourth quarter valued at about $20,777,000. Omega Fund Management LLC bought a new stake in shares of enGene during the fourth quarter valued at about $10,441,000. Finally, Vivo Capital LLC bought a new stake in shares of enGene during the fourth quarter valued at about $6,264,000. 64.16% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. SVB Leerink assumed coverage on enGene in a research note on Tuesday, February 20th. They set an “outperform” rating and a $31.00 target price on the stock. UBS Group assumed coverage on enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock. Wells Fargo & Company assumed coverage on enGene in a research note on Monday. They set an “overweight” rating and a $30.00 target price on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. Finally, Guggenheim initiated coverage on enGene in a research note on Monday, April 15th. They set a “buy” rating and a $34.00 target price on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $34.40.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.